Blueprint Medicines Corporation reported global AYVAKIT net product revenues of $479.0 million for the full year 2024, representing a 135% increase from the prior year. Fourth-quarter 2024 AYVAKIT net product revenues reached $144.1 million, contributing to total revenues of $508.824 million for the full year, compared to $249.380 million in 2023.
For 2025, Blueprint Medicines anticipates global AYVAKIT net product revenues to be approximately $680 million to $710 million, which represents a 45% year-over-year growth at the midpoint. The company reaffirmed its projection for AYVAKIT to achieve $2 billion in revenue by 2030 and reiterated the $4 billion peak systemic mastocytosis (SM) franchise revenue opportunity.
The company reported a net loss of $(67.089) million, or $(1.07) per share, for the full year 2024, a significant improvement from a net loss of $(506.984) million, or $(8.37) per share, in 2023. Blueprint Medicines reduced its operating cash burn by over 50% in 2024 and expects further reductions in 2025. The company ended 2024 with $863.937 million in cash, cash equivalents, and investments, indicating a durable capital position to achieve a self-sustainable financial profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.